Legal Representation
Attorney
Sarah Anne Keefe
USPTO Deadlines
Application History
26 events| Date | Code | Type | Description |
|---|---|---|---|
| Dec 4, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Dec 4, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| May 2, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 30, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 30, 2023 | EXT3 | S | SOU EXTENSION 3 FILED |
| Apr 30, 2023 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Nov 2, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 31, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Oct 31, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Oct 31, 2022 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Oct 31, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Oct 31, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 31, 2022 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 31, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED |
| May 3, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 29, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Apr 29, 2022 | EXT1 | S | SOU EXTENSION 1 FILED |
| Apr 29, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Nov 2, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Sep 7, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Sep 7, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 18, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 4, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Aug 3, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Apr 21, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jan 23, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of WHIM syndrome; Pharmaceutical preparations for the treatment of immunodeficiencies; Pharmaceutical preparations for the treatment of neutropenia; Pharmaceutical preparations for the treatment of Waldenström's macroglobulinemia; Pharmaceutical preparations for the treatment of cancer
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005